Clinical trial NCT03998657: Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions
Official title: A Continued Access Study to Evaluate Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Prostate Cancer
Lead sponsor: InSightec
Sponsor class: INDUSTRY
First posted: 2019-06-26
Enrollment: 14
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This extended clinical investigation is a multicenter, prospective, single arm study intended to provide continued access of the Exablate Model 2100 device (Exablate Prostate) to patients for treatment of prostate lesions and collect additional safety and effectiveness data during the 510(k) preparation and review period.


Eligibility criteria: Inclusion Criteria:

* Biopsy proven adenocarcinoma of the prostate
* Intermediate risk, organ-confined prostate cancer (T1a up to T2b) and voluntarily chooses Exablate, who may currently be on watchful waiting or active surveillance and not in need of imminent radical therapy
* Up to 2 MRI visible Gleason 7 confirmed on mapping prostate biopsy that Investigator deems treatable within a single treatment session; may have secondary Gleason 6 on ipsilateral or contralateral side confirmed with biopsy and/or MRI
* PSA less than or equal to 20ng/mL

Exclusion Criteria:

* Evidence of distant prostate cancer including lymph node involvement and/or metastasis of cancer
* Subject undergoing androgen deprivation therapy, initiating any new medication that can affect PSA, or history of bilateral orchiectomy
* Active bladder cancer, active UTI, or untreated prostatitis
* Untreated urethral stricture/bladder neck contracture
* Prostate-specific chemotherapy, brachytherapy, cryotherapy, photodynamic therapy, radical prostatectomy, or focal therapy (excluding FUS); or any prior radiation therapy to the pelvis for prostate cancer or any other malignancy
* Subjects with pathology or implants that may adversely impact treatment due to acoustics, imaging, or safe probe insertion
* Subject not able or willing to tolerate the required prolonged stationary supine position during treatment
* Contraindications to MRI

Primary outcomes:
measure: Incidence and severity of device/procedure-related complications following treatment
timeFrame: 12 months
measure: Proportions of treated subjects reporting negative Gleason 7 biopsy within the prostate biopsy treatment area.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
city: Delray Beach
country: United States
facility: Sperling Prostate Center
state: Florida
city: Boston
country: United States
facility: Brigham & Women's Hospital
state: Massachusetts
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
Study officials:
References: